Pennine MSK Partnership works with the research arm of the NHS, the National Institute for Health Research, to promote clinical research and offer our patients the opportunity to take part in ethically approved research studies.
Click to see how we support NHS Research and how you can help and get involved.
OTTER II Trial
The OTTER II study is to evaluate the clinical effectiveness and efficacy of thumb splints for osteoarthritis (OA) of the thumb. We would like to compare three approaches over 12 weeks and measure which one is most useful. This will help us identify the best therapy for patients with thumb base OA. One of three specific therapy approaches will be randomly selected to treat your thumb. It is not yet known which approach is the most useful one, this is the reason they are being compared. In all treatment options you will receive optimal occupational therapy/physiotherapy self-management care (as normally available through the NHS). You may or may not also receive a splint to wear.
Audit and National Registers
National Early Inflammatory Arthritis Audit
The National Early Inflammatory Arthritis Audit has been commissioned to help understand and improve the quality of care for people with arthritis. The project collects information on people referred to rheumatology units with a possible arthritis. This is an opportunity to contribute to a national study which will shape the scope of inflammatory arthritis treatment in the future, and help improve referrals and treatment for the next generation. Pennine MSK will provide information about your care over the first 12 months after you have been diagnosed. In addition you are asked how arthritis is affecting your life. This is in the form of an online questionnaire (paper format available if preferred) three times over 12 months – when you are diagnosed, after 3 months and one year after your diagnosis.
British Society for Rheumatology Biologics Register (BSRBR)
The BSRBR-RA (British Society for Rheumatology Biologics Register –Rheumatoid Arthritis) is run by the Arthritis Research UK Epidemiology Unit at the University of Manchester. It tracks the progress of patients with severe Rheumatoid Arthritis (RA), who are receiving biologic agents Benepali, Cimzia, Enbrel, Erelzi, Flixabi, Humira, Inflectra, Kevzara, Olumiant, Remsima, Remicade, Rixathon, RoActemra and Xeljanz, and monitoring the safety and effectiveness of these treatments over a long-term period. For more information refer to the BSRBR website here